Compare · BSX vs MDAI
BSX vs MDAI
Side-by-side comparison of Boston Scientific Corporation (BSX) and Spectral AI Inc. (MDAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and MDAI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $69.68B, about 1396.7x MDAI ($49.9M).
- Over the past year, BSX is down 54.9% and MDAI is down 18.4% - MDAI leads by 36.5 points.
- MDAI has been more active in the news (6 items in the past 4 weeks vs 5 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 1 for MDAI).
- Company
- Boston Scientific Corporation
- Spectral AI Inc.
- Price
- $48.09-0.42%
- $1.55-1.59%
- Market cap
- $69.68B
- $49.9M
- 1M return
- -0.71%
- -4.02%
- 1Y return
- -54.90%
- -18.42%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 6
- Recent ratings
- 25
- 1
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
Latest MDAI
- Spectral AI to Present at H.C. Wainwright 28th Annual Global Investment Conference
- Director Dimaio John Michael was granted 35,000 shares, increasing direct ownership by 1% to 2,766,847 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Spectral AI Inc.
- Spectral AI Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Spectral AI Announces 2026 Second Quarter Financial Results
- SEC Form 10-Q filed by Spectral AI Inc.
- Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call
- Spectral AI Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Spectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication
- Director Dimaio John Michael was granted 44,000 shares, increasing direct ownership by 2% to 2,731,847 units (SEC Form 4)